GSK shuffles top management

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) reshuffled its executive management as it prepares to integrate the vaccines business it is acquiring from Novartis AG (NYSE:NVS; SIX:NOVN) in an asset-swapping deal announced in April. The shake-up was announced along with third-quarter earnings (see BioCentury, April 28).

Moncef Slaoui, previously chairman of global pharmaceuticals R&D and vaccines, will become chairman of global vaccines. Patrick Vallance will remain president of pharmaceutical R&D and take sole responsibility for GSK's R&D activities in pharmaceuticals. The two executives previously shared pharmaceutical R&D responsibilities. Slaoui remains a member of GSK's board. ...